international standards, as an instrumental and essential prerequisite to the establishment and effective implementation of adequate and appropriate legislation covering all aspects of products for veterinary use, including registration, quality control, distribution, monitoring of quantities and final use.

• Develop and improve international and regional cooperation in the establishment and enforcement of legislation to harmonize the regulatory framework between OIE Member States so as to assist countries in need to effectively institute and maintain such mechanisms.

• Encourage countries to allocate appropriate human and financial resources to veterinary services and laboratories to correctly implement the OIE standards and guidelines related to veterinary products and their control.

• Enhance capacities of national focal points for OIE on matters related to veterinary products according to the suggested terms of reference and encourage his/her participation in training sessions and appropriate international gatherings and meetings.

• Promote the responsible and prudent use of veterinary medicinal products, in particular of antimicrobials used in veterinary medicine, and the monitoring of the quantities used and potential existence or development of antimicrobial resistance in diseasecausing organisms affecting both humans and animals.

• Actively encourage the recognition and application of the international recommendations, guidelines and tools developed by the OIE and adopted by the World Assembly of Delegates on veterinary products.

C. Eligibility Information

The following organizations/ institutions are eligible to apply: The OIE.

II. Award Information/Funds Available

A. Award Amount

FDA anticipates providing one award of \$565,000 (total costs including indirect costs) in fiscal year (FY) 2010 in support of this project. Subject to the availability of funds and successful performance, 1 additional year of support up to \$565,000 per year will be available.

B. Length of Support

The support will be 1 year with the possibility of an additional year of noncompetitive support. Continuation beyond the first year will be based on satisfactory performance during the preceding year, receipt of a noncompeting continuation application and available Federal FY appropriations.

Dated: September 29, 2010.

Leslie Kux,

Acting Assistant Commissioner for Policy. [FR Doc. 2010–24905 Filed 10–4–10; 8:45 am] BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Notice of Listing of Members of the National Institutes of Health's Senior Executive Service 2010 Performance Review Board (PRB)

The National Institutes of Health (NIH) announces the persons who will serve on the National Institutes of Health's Senior Executive Service 2010 Performance Review Board. This action is being taken in accordance with Title 5, U.S.C., 4314(c)(4), which requires that members of performance review boards be appointed in a manner to ensure consistency, stability, and objectivity in performance appraisals and requires that notice of the appointment of an individual to serve as a member be published in the **Federal Register**.

The following persons will serve on the NIH Performance Review Board, which oversees the evaluation of performance appraisals of NIH Senior Executive Service (SES) members:

Ms. Colleen Barros (Chair), Dr. Michael Gottesman, Ms. Lenora Johnson, Ms. Robin Kawazoe, Dr. Sally Rockey, Dr. Lawrence Tabak, Dr. Samir Zakhari.

For further information about the NIH Performance Review Board, contact the Office of Human Resources, Workforce Relations Division, National Institutes of Health, Building 31, Room B3C07, Bethesda, Maryland 20892, telephone 301–402–9203 (not a toll-free number).

Dated: September 27, 2010.

Francis S. Collins,

Director, National Institutes of Health. [FR Doc. 2010–24929 Filed 10–4–10; 8:45 am] BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Advisory Committee to the Director (ACD), Centers for Disease Control and Prevention (CDC)—Health Disparities Subcommittee (HDS)

Correction: This notice was published in the **Federal Register** on September 1, 2010, Volume 75, Number 169, page 53703. A quorum of the subcommittee's membership was not able to participate; therefore, the meeting was adjourned. The subcommittee will reconvene as follows:

Time and Date: 2 p.m.–3 p.m., October 21, 2010.

Place: Teleconference.

Status: Open to the public. Teleconference access limited only by the availability of telephone ports. The public is welcome to participate during the public comment period, which is tentatively scheduled from 2:45 p.m. to 2:50 p.m. To participate in the teleconference please dial (877) 394– 7734 and enter conference code 9363147.

Purpose: The Subcommittee will provide recommendations for consideration to the ACD on strategic and other broad issues facing CDC.

Matters To Be Discussed: Policy brief on health equity and social determinants of health; update on collaboration with the CDC Health Equity Workgroup; CDC Director's Annual Health Disparity Report; and briefing on the realignment of the CDC Office of Minority Health and Health Disparities. Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Walter W. Williams, M.D., M.P.H., Designated Federal Officer, HDS, ACD, CDC, 1600 Clifton Road, NE., M/S E–67, Atlanta, Georgia 30333. Telephone (404) 498–2310, E-mail: http:// www1@cdc.gov.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: September 29, 2010.

Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2010–24911 Filed 10–4–10; 8:45 am] BILLING CODE 4163–18–P